Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
Current Bladder Dysfunction Reports
Erschienen in: Current Bladder Dysfunction Reports 4/2017

18.11.2017 | Neurogenic Bladder (C Powell, Section Editor)

Clinical Factors to Decide Between Sacral Neuromodulation and Onabotulinum Toxin—When Is One Clearly Better?

verfasst von: Laura N. Nguyen, Esther Han, Alec Wilson, Jason P. Gilleran

Erschienen in: Current Bladder Dysfunction Reports | Ausgabe 4/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

This article provides a review of the current literature on the applicability of each treatment for OAB, as well as unique clinical scenarios. In addition, the authors provide their own practical insight on how to approach third-line therapies for OAB.

Recent Findings

The treatment of overactive bladder (OAB) is increasingly common amongst specialists. OnabotulinumtoxinA and sacral neuromodulation are both highly effective third-line therapies for OAB, but work via very different mechanisms. The differences between the two are associated with potential benefits and complications unique for each.

Summary

The OAB clinician must account for several clinical and personal factors in counseling patients on options.
Literatur
1.
Haylen BT, de Ridder D, Freeman RM, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Int Urogynecol J. 2010;21(1):5–26.PubMedCrossRef
2.
Coyne KS, Sexton CC, Vats V, et al. National community prevalence of overactive bladder in the United States stratified by sex and age. Urology. 2011;77(5):1081–7.PubMedCrossRef
3.
Gormley EA, Lightner DJ, Faraday M, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment. J Urol. 2015;193(5):1572–80.PubMedCrossRef
4.
Veenboer PW, Bosch JL. Long-term adherence to antimuscarinic therapy in everyday practice: a systematic review. J Urol. 2014;191(4):1003–8.PubMedCrossRef
5.
Smith A, Bevan D, Douglas HR, et al. Management of urinary incontinence in women: summary of updated NICE guidance. BMJ. 2013;f5170:347.
6.
Rachaneni S, Latthe P. Effectiveness of BTX-A and neuromodulation in treating OAB with or without detrusor overactivity: a systematic review. Int Urogynecol J. 2017;28(6):805–16.PubMedCrossRef
7.
South MM, Romero AA, Jamison MG, et al. Detrusor overactivity does not predict outcome of sacral neuromodulation test stimulation. Int Urogynecol J Pelvic Floor Dysfunct. 2007;18(12):1395–8.PubMedCrossRef
8.
Chancellor MB. OnabotulinumtoxinA for overactive bladder and urinary incontinence. J Urol. 2017;197(2S):S224–S5.PubMedCrossRef
9.
Dolly O. Synaptic transmission: inhibition of neurotransmitter release by botulinum toxins. Headache. 2003;43(Suppl 1):S16–24.PubMedCrossRef
10.
Söllner T, Whiteheart SW, Brunner M, et al. SNAP receptors implicated in vesicle targeting and fusion. Nature. 1993;362(6418):318–24.PubMedCrossRef
11.
Dmochowski R, Chapple C, Nitti VW, et al. Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial. J Urol. 2010;184(6):2416–22.PubMedCrossRef
12.
Smith CP, Boone TB, de Groat WC, et al. Effect of stimulation intensity and botulinum toxin isoform on rat bladder strip contractions. Brain Res Bull. 2003;61(2):165–71.PubMedCrossRef
13.
Yoshida M, Miyamae K, Iwashita H, et al. Management of detrusor dysfunction in the elderly: changes in acetylcholine and adenosine triphosphate release during aging. Urology. 2004;63(3 Suppl 1):17–23.PubMedCrossRef
14.
Khera M, Somogyi GT, Kiss S, et al. Botulinum toxin A inhibits ATP release from bladder urothelium after chronic spinal cord injury. Neurochem Int. 2004;45(7):987–93.PubMedCrossRef
15.
Apostolidis A, Dasgupta P, Fowler CJ. Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity. Eur Urol. 2006;49(4):644–50.PubMedCrossRef
16.
Anger JT, Weinberg A, Suttorp MJ, et al. Outcomes of intravesical botulinum toxin for idiopathic overactive bladder symptoms: a systematic review of the literature. J Urol. 2010;183(6):2258–64.PubMedPubMedCentralCrossRef
17.
Chapple C, Sievert KD, MacDiarmid S, et al. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial. Eur Urol. 2013;64(2):249–56.PubMedCrossRef
18.
• Nitti VW, Dmochowski R, Herschorn S, et al. OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial. J Urol. 2017;197(2S):S216–S23. The EMBARK trial was a prospective randomized trial that compared urge incontinence episodes in patients receiving onabotulinumtoxinA injections to placebo. 23% of patients were continent following treatment with onabotulinumtoxinA, compared to 7% in the placebo group. PubMedCrossRef
19.
Drake MJ, Nitti VW, Ginsberg DA, et al. Comparative assessment of the efficacy of onabotulinumtoxinA and oral therapies (anticholinergics and mirabegron) for overactive bladder: a systematic review and network meta-analysis. BJU Int. 2017. https://​doi.​org/​10.​1111/​bju.​13945.
20.
Nitti VW, Ginsberg D, Sievert KD, et al. Durable efficacy and safety of long-term onabotulinumtoxinA treatment in patients with overactive bladder syndrome: final results of a 3.5-year study. J Urol. 2016;196(3):791–800.PubMedCrossRef
21.
22.
Sahai A, Khan MS, Dasgupta P. Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo controlled trial. J Urol. 2007;177(6):2231–6.PubMedCrossRef
23.
24.
Peters KM, Kandagatla P, Killinger KA, et al. Clinical outcomes of sacral neuromodulation in patients with neurologic conditions. Urology. 2013;81(4):738–43.PubMedCrossRef
25.
Engeler DS, Meyer D, Abt D, et al. Sacral neuromodulation for the treatment of neurogenic lower urinary tract dysfunction caused by multiple sclerosis: a single-centre prospective series. BMC Urol. 2015;15:105.PubMedPubMedCentralCrossRef
26.
Puccini F, Bhide A, Elneil S, et al. Sacral neuromodulation: an effective treatment for lower urinary tract symptoms in multiple sclerosis. Int Urogynecol J. 2016;27(3):347–54.PubMedCrossRef
27.
Schober MS, Ching CB, Peters KM, et al. Novel use of pudendal neuromodulation in a pediatric patient with caudal regression and partial sacral agenesis for refractory bowel bladder dysfunction. Urology. 2016;94:224–6.PubMedCrossRef
28.
29.
Amend B, Khalil M, Kessler TM, et al. How does sacral modulation work best? Placement and programming techniques to maximize efficacy. Curr Urol Rep. 2011;12(5):327–35.PubMedCrossRef
30.
Le NB, Kim JH. Expanding the role of neuromodulation for overactive bladder: new indications and alternatives to delivery. Curr Bladder Dysfunct Rep. 2011;6(1):25–30.PubMedCrossRef
31.
Siegel S, Noblett K, Mangel J, et al. Results of a prospective, randomized, multicenter study evaluating sacral neuromodulation with InterStim therapy compared to standard medical therapy at 6-months in subjects with mild symptoms of overactive bladder. Neurourol Urodyn. 2015;34(3):224–30.PubMedCrossRef
32.
Noblett K, Siegel S, Mangel J, et al. Results of a prospective, multicenter study evaluating quality of life, safety, and efficacy of sacral neuromodulation at twelve months in subjects with symptoms of overactive bladder. Neurourol Urodyn. 2016;35(2):246–51.PubMedCrossRef
33.
• Siegel S, Noblett K, Mangel J, et al. Five-year follow-up results of a prospective, multicenter study in overactive bladder subjects treated with sacral neuromodulation. J Urol. 2017. https://​doi.​org/​10.​1016/​j.​juro.​2017.​07.​010. The InSite trial followed patients with overactive bladder after initiation of sacral neuromodulation. Overall therapeutic success rate was 82% at five years, and 45% of patients were completely dry.
34.
Spinelli M, Giardiello G, Gerber M, et al. New sacral neuromodulation lead for percutaneous implantation using local anesthesia: description and first experience. J Urol. 2003;170(5):1905–7.PubMedCrossRef
35.
Siddiqui NY, Amundsen CL, Corey EG, et al. Lead migration after sacral neuromodulation: surgical revision in fascial versus tined anchoring systems. Int Urogynecol J. 2011;22(4):419–23.PubMedCrossRef
36.
Hoag N, Plagakis S, Pillay S, et al. Sacral neuromodulation for refractory overactive bladder after prior intravesical onabotulinumtoxinA treatment. Neurourol Urodyn. 2017;36(5):1377–81.PubMedCrossRef
37.
Bartley JM, Killinger KA, Boura JA, et al. The impact of prior back surgery on neuromodulation outcomes: a review of over 500 patients. Neurourol Urodyn. 2017;36(6):1535–42.PubMedCrossRef
38.
White WM, Mobley JD 3rd, Doggweiler R, et al. Incidence and predictors of complications with sacral neuromodulation. Urology. 2009;73(4):731–5.PubMedCrossRef
39.
Latini JM, Alipour M, Kreder KJ Jr. Efficacy of sacral neuromodulation for symptomatic treatment of refractory urinary urge incontinence. Urology. 2006;67(3):550–3. discussion 3–4PubMedCrossRef
40.
van Kerrebroeck PE, van Voskuilen AC, Heesakkers JP, et al. Results of sacral neuromodulation therapy for urinary voiding dysfunction: outcomes of a prospective, worldwide clinical study. J Urol. 2007;178(5):2029–34.PubMedCrossRef
41.
Brazzelli M, Murray A, Fraser C. Efficacy and safety of sacral nerve stimulation for urinary urge incontinence: a systematic review. J Urol. 2006;175(3):835–41.PubMedCrossRef
42.
43.
Siegel S, Noblett K, Mangel J, et al. Three-year follow-up results of a prospective, multicenter study in overactive bladder subjects treated with sacral neuromodulation. Urology. 2016;94:57–63.PubMedCrossRef
44.
Cohn JA, Kowalik CG, Kaufman MR, et al. Evaluation of the axonics modulation technologies sacral neuromodulation system for the treatment of urinary and fecal dysfunction. Expert Rev Med Devices. 2017;14(1):3–14.PubMedCrossRef
45.
Siegel SW, Catanzaro F, Dijkema HE, et al. Long-term results of a multicenter study on sacral nerve stimulation for treatment of urinary urge incontinence, urgency-frequency, and retention. Urology. 2000;56(6):87–91.PubMedCrossRef
46.
Hijaz A, Vasavada SP, Daneshgari F, et al. Complications and troubleshooting of two-stage sacral neuromodulation therapy: a single-institution experience. Urology. 2006;68(3):533–7.PubMedCrossRef
47.
Blandon RE, Gebhart JB, Lightner DJ, et al. Re-operation rates after permanent sacral nerve stimulation for refractory voiding dysfunction in women. BJU Int. 2008;101(9):1119–23.PubMedCrossRef
48.
Peters KM, Killinger KA, Gilleran JP, et al. Predictors of reoperation after sacral neuromodulation: a single institution evaluation of over 400 patients. Neurourol Urodyn. 2017;36(2):354–9.PubMedCrossRef
49.
Kalsi V, Popat RB, Apostolidis A, et al. Cost-consequence analysis evaluating the use of botulinum neurotoxin-A in patients with detrusor overactivity based on clinical outcomes observed at a single UK centre. Eur Urol. 2006;49(3):519–27.PubMedCrossRef
50.
Siddiqui NY, Amundsen CL, Visco AG, et al. Cost-effectiveness of sacral neuromodulation versus intravesical botulinum a toxin for treatment of refractory urge incontinence. J Urol. 2009;182(6):2799–804.PubMedCrossRef
51.
Bertapelle MP, Vottero M, Popolo GD, et al. Sacral neuromodulation and Botulinum toxin A for refractory idiopathic overactive bladder: a cost-utility analysis in the perspective of Italian Healthcare System. World J Urol. 2015;33(8):1109–17.PubMedCrossRef
52.
Leong RK, de Wachter SG, Joore MA, et al. Cost-effectiveness analysis of sacral neuromodulation and botulinum toxin A treatment for patients with idiopathic overactive bladder. BJU Int. 2011;108(4):558–64.PubMedCrossRef
53.
Whitehead WE, Borrud L, Goode PS, et al. Fecal incontinence in US adults: epidemiology and risk factors. Gastroenterology. 2009;137(2):512–7. 7 e1-2.PubMedPubMedCentralCrossRef
54.
Meyer I, Richter HE. Impact of fecal incontinence and its treatment on quality of life in women. Womens Health (Lond). 2015;11(2):225–38.CrossRef
55.
56.
Devroede G, Giese C, Wexner SD, et al. Quality of life is markedly improved in patients with fecal incontinence after sacral nerve stimulation. Female Pelvic Med Reconstr Surg. 2012;18(2):103–12.PubMedCrossRef
57.
McNevin MS, Moore M, Bax T. Outcomes associated with Interstim therapy for medically refractory fecal incontinence. Am J Surg. 2014;207(5):735–7. discussion 7–88.PubMedCrossRef
58.
Janssen PT, Kuiper SZ, Stassen LP, et al. Fecal incontinence treated by sacral neuromodulation: long-term follow-up of 325 patients. Surgery. 2017;161(4):1040–8.PubMedCrossRef
59.
Coyne KS, Cash B, Kopp Z, et al. The prevalence of chronic constipation and faecal incontinence among men and women with symptoms of overactive bladder. BJU Int. 2011;107(2):254–61.PubMedCrossRef
60.
Ghazwani YQ, Elkelini MS, Hassouna MM. Efficacy of sacral neuromodulation in treatment of bladder pain syndrome: long-term follow-up. Neurourol Urodyn. 2011;30(7):1271–5.PubMed
61.
Marcelissen T, Jacobs R, van Kerrebroeck P, et al. Sacral neuromodulation as a treatment for chronic pelvic pain. J Urol. 2011;186(2):387–93.PubMedCrossRef
62.
Kuo HC, Jiang YH, Tsai YC, et al. Intravesical botulinum toxin-a injections reduce bladder pain of interstitial cystitis/bladder pain syndrome refractory to conventional treatment—a prospective, multicenter, randomized, double-blind, placebo-controlled clinical trial. Neurourol Urodyn. 2016;35(5):609–14.PubMedCrossRef
63.
Morrissey D, El-Khawand D, Ginzburg N, et al. Botulinum toxin a injections into pelvic floor muscles under electromyographic guidance for women with refractory high-tone pelvic floor dysfunction: a 6-month prospective pilot study. Female Pelvic Med Reconstr Surg. 2015;21(5):277–82.PubMedCrossRef
64.
Abrams P, Andersson KE, Birder L, et al. Fourth International Consultation on Incontinence Recommendations of the International Scientific Committee: evaluation and treatment of urinary incontinence, pelvic organ prolapse, and fecal incontinence. Neurourol Urodyn. 2010;29(1):213–40.PubMedCrossRef
65.
Kurpad R, Kennelly MJ. The evaluation and management of refractory neurogenic overactive bladder. Curr Urol Rep. 2014;15(10):444.PubMedCrossRef
66.
Schurch B, Stohrer M, Kramer G, et al. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol. 2000;164(3 Pt 1):692–7.PubMedCrossRef
67.
Schurch B, de Seze M, Denys P, et al. Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol. 2005;174(1):196–200.PubMedCrossRef
68.
Cheng T, Shuang WB, Jia DD, et al. Efficacy and safety of OnabotulinumtoxinA in patients with neurogenic detrusor Overactivity: a systematic review and meta-analysis of randomized controlled trials. PLoS One. 2016;11(7):e0159307.PubMedPubMedCentralCrossRef
69.
Hohenfellner M, Schultz-Lampel D, Dahms S, et al. Bilateral chronic sacral neuromodulation for treatment of lower urinary tract dysfunction. J Urol. 1998;160(3 Pt 1):821–4.PubMedCrossRef
70.
Ishigooka M, Suzuki Y, Hashimoto T, et al. A new technique for sacral nerve stimulation: a percutaneous method for urinary incontinence caused by spinal cord injury. Br J Urol. 1998;81(2):315–8.PubMedCrossRef
71.
Chartier-Kastler EJ, Ruud Bosch JL, Perrigot M, et al. Long-term results of sacral nerve stimulation (S3) for the treatment of neurogenic refractory urge incontinence related to detrusor hyperreflexia. J Urol. 2000;164(5):1476–80.PubMedCrossRef
72.
Hohenfellner M, Humke J, Hampel C, et al. Chronic sacral neuromodulation for treatment of neurogenic bladder dysfunction: long-term results with unilateral implants. Urology. 2001;58(6):887–92.PubMedCrossRef
73.
Kessler TM, La Framboise D, Trelle S, et al. Sacral neuromodulation for neurogenic lower urinary tract dysfunction: systematic review and meta-analysis. Eur Urol. 2010;58(6):865–74.PubMedCrossRef
74.
Knupfer SC, Liechti MD, Mordasini L, et al. Protocol for a randomized, placebo-controlled, double-blind clinical trial investigating sacral neuromodulation for neurogenic lower urinary tract dysfunction. BMC Urol. 2014;14:65.PubMedPubMedCentralCrossRef
75.
•• Amundsen CL, Richter HE, Menefee SA, et al. OnabotulinumtoxinA vs sacral neuromodulation on refractory urgency urinary incontinence in women: a randomized clinical trial. JAMA. 2016;316(13):1366–74. This is the only randomized trial comparing onabotulinumtoxinA to sacral neuromodulation in patients with refractory urge incontinence. A total of 364 women were included, and the primary outcome was mean reduction in number of urge incontinence episodes, which was greater in patients undergoing onabotulinumtoxinA injection. PubMedPubMedCentralCrossRef
76.
Anger JT, Cameron AP, Madison R, et al. Predictors of implantable pulse generator placement after sacral neuromodulation: who does better? Neuromodulation. 2014;17(4):381–4. discussion 4PubMedCrossRef
77.
Blok BF. OnabotulinumtoxinA vs sacral neuromodulation for urgency incontinence. JAMA. 2017;317(5):534–5.PubMedCrossRef
78.
Malmsten UG, Molander U, Peeker R, et al. Urinary incontinence, overactive bladder, and other lower urinary tract symptoms: a longitudinal population-based survey in men aged 45-103 years. Eur Urol. 2010;58(1):149–56.PubMedCrossRef
Metadaten
Titel
Clinical Factors to Decide Between Sacral Neuromodulation and Onabotulinum Toxin—When Is One Clearly Better?
verfasst von
Laura N. Nguyen
Esther Han
Alec Wilson
Jason P. Gilleran
Publikationsdatum
18.11.2017
Verlag
Springer US
Erschienen in
Current Bladder Dysfunction Reports / Ausgabe 4/2017
Print ISSN: 1931-7212
Elektronische ISSN: 1931-7220
DOI
https://doi.org/10.1007/s11884-017-0454-z

Weitere Artikel der Ausgabe 4/2017

Current Bladder Dysfunction Reports 4/2017 Zur Ausgabe

Reconstructed Bladder Function & Dysfunction (M Kaufman, Section Editor)

Long-Term Voiding Outcomes After Adult Urethral Reconstruction for Stricture Disease

Reconstructed Bladder Function & Dysfunction (M Kaufman, Section Editor)

Voiding Dysfunction, Incontinence, and Erectile Dysfunction Following High-Intensity Focus Ultrasound and Focal Cryotherapy in Treatment of Prostate Cancer

Reconstructed Bladder Function & Dysfunction (M Kaufman, Section Editor)

Risk Factors for Infection Following Third-line Therapy for Overactive Bladder

Reconstructed Bladder Function & Dysfunction (M Kaufman, Section Editor)

Current Concepts in Urinary Biomarkers for Overactive Bladder: What Is the Evidence?

Reconstructed Bladder Function & Dysfunction (M Kaufman, Section Editor)

Impact of Autonomic Dysfunction on Lower Urinary Tract Symptoms

Inflammatory/Infectious Bladder Disorders (MS Mourad, Section Editor)

Urethral Syndrome: Updates and Highlights on Current Management

Neu im Fachgebiet Urologie

18.04.2024 | Infertilität | Nachrichten

Viele Ärzte haben Probleme mit der Zeugungsfähigkeit

17.04.2024 | Postoperative nausea and vomiting | Nachrichten

Hochrisiko-Eingriffe für postoperative Übelkeit

10.04.2024 | PSA-Screening | Nachrichten

Einladung zum PSA-Screening senkt die Krebssterblichkeit

08.04.2024 | Andrologie | Nachrichten

Wie toxische Männlichkeit der Gesundheit von Männern schadet
weitere anzeigen

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen